Paul Edwards Posted February 28, 2014 Share Posted February 28, 2014 In today's teleconference Tony Maxwell mentioned several clinical trials in relation to the drug Enzalutamide which are currently recruiting: PROSPER Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Click on this link for more details PLATO Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Click on this link for more details Alpharadin (also known as Radium-223 and Xofigo) The ALSYMPCA Clinical Trial mentioned on the Prostate Cancer Foundation of Australia website is no longer recruiting participants. Two new Alpharadin clinical trials are about to commence recruiting Australian participants. Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Active but not yet recruiting. Study Start Date March 2014 Click here for more details Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone Active but not yet recruiting. Study Start Date March 2014 Click here for more details Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.